Sars-CoV-2 virusvarianttiseurannasta

 https://www.who.int/activities/tracking-SARS-CoV-2-variants

Currently circulating variants of interest (VOIs) (as of 9 February 2024)

 

 

Pango lineage	Nextstrain clade	Genetic features	Earliest documented samples	Date of designation and risk assessments
XBB.1.5	23A	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1, with a breakpoint in S1.  XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.9.1) Includes XBB.1.5.70 (23G): XBB.1.5 + S:L455F and S:F456L	21-10-2022	11-01-2023 XBB.1.5 Rapid Risk Assessment, 11 January 2023 XBB.1.5 Updated Rapid Risk Assessment, 25 January 2023 XBB.1.5 Updated Risk Assessment, 24 February 2023 XBB.1.5 Updated Risk Assessment, 20 June 2023
XBB.1.16	23B	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1 XBB.1 + S:E180V, S:K478R and S:F486P	09-01-2023	17-04-2023 XBB.1.16 Initial Risk Assessment, 17 April 2023 XBB.1.16 Updated Risk Assessment, 05 June 2023
EG.5	Not assigned	XBB.1.9.2 + S:F456L Includes EG.5.1 (23F): EG.5 + S:Q52H HK.3 (23H): EG.5 + S:Q52H, S:L455F HV.1: EG.5 + S:Q52H, S:F157L, S:L452R	17-02-2023	09-08-2023 EG.5 Initial Risk Evaluation, 09 August 2023 EG.5 Updated Risk Evaluation, 21 September 2023 EG.5 Updated Risk Evaluation, 21 November 2023
BA.2.86$	23I	Mutations relative to BA.2	24-07-2023	21-11-2023 BA.2.86 Initial Risk Evaluation, 21 November 2023
JN.1	Not assigned	BA.2.86 + S:L455S	25-08-2023	09-02-2024 JN.1 Initial Risk Evaluation 18 December 2023 JN.1 Updated Risk Evaluation 9 February 2024

 

 

Currently circulating variants under monitoring (VUMs) (as of 29 January 2024)

 

Pango lineage§	Nextstrain clade	Genetic features	Earliest documented samples	Date of designation and risk assessments
XBB*	22F	BA.2+ S:V83A, S:Y144-, S:H146Q, S:Q183E, S:V213E, S:G252V, S:G339H, S:R346T, S:L368I, S:V445P, S:G446S, S:N460K, S:F486S, S:F490S	19-08-2022	12-10-2022
XBB.1.9.1	23D	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1 XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.5)	05-12-2022	30-03-2023
XBB.2.3	23E	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1 XBB + S:D253G, S:F486P, S:P521S	09-12-2022	17-05-2023

 

^$ Excludes BA.2.86 sublineages listed here as VOIs.

^* Excludes XBB sublineages listed here as VOIs and VUMs.

^§ A VUM is de-escalated if its prevalence is <1% at the global level and in all WHO regions for 8 consecutive weeks.

 

 

 

Technical Advisory Groups